Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Autor: Helena Fohlin, Anna Nordenskjöld, Johan Rosell, Mårten Fernö, Tommy Fornander, Lisa Rydén, Lambert Skoog, Bo Nordenskjöld, Olle Stål

Publikováno v: Acta Oncologica, Vol 63, Iss 1 (2024)

Background: Hormone receptor positivity predicts benefit from endocrine therapy but the knowledge about the long-term survival of patients with different tumor receptor levels is limited. In this study, we describe the 25 years outcome of tamoxifen (

Externí odkaz: https://doaj.org/article/70fb0a9414d446158f65dbae4436b48e

First report from the meta-analysis of the randomized trials NORDIC, NOA-8 and CE.6 on elderly patients with glioblastoma

Autor: Annika Malmstrom, Eva Cantagallo, Chris O Callaghan, Wolfgang Wick, Bjorn Henning Gronberg, Normand Laperriere, Johan Rosell, Christine Marosi, Michael Weller, James Perry, Alba A Brandes, Guido Reifenberger, Johan Menten, Christoph Meisner, Felix Oppong, Thierry Gorlia

Publikováno v: WFNOS 2022 Abstract Book.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5199bc037f1eae40e869b3378af87192
https://doi.org/10.14791/btrt.2022.10.f-1185

Sex Disparities in

Autor: Anja, Smits, Malgorzata, Lysiak, Andreas, Magnusson, Johan, Rosell, Peter, Söderkvist, Annika, Malmström

Publikováno v: Journal of Clinical Medicine

Introduction: Recent studies suggest an overrepresentation of MGMT promoter methylated tumors in females with IDHwt glioblastoma (GBM) compared to males, with a subsequent better response to alkylating treatment. Methods: To reveal sex-bound associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::31e901ff81aa6506cba675e9b8c9b799
https://pubmed.ncbi.nlm.nih.gov/33546098

Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Autor: Jenny Isaksson, Henrik Gréen, Elisabeth Åvall-Lundqvist, Linn Pettersson, Mats Anden, Nils O. Elander, Dimitrios Papantoniou, Johan Rosell

Publikováno v: World Journal of Clinical Oncology

BACKGROUNDThe majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC). Following months to years of ADT, the di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f164bdf43fed912a52f999c2f350c737
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181923

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis

Autor: Malgorzata Lysiak, Peter Söderkvist, Hans Skovgaard Poulsen, Johan Rosell, Annika Malmström, J. Dowsett, Rikke Hedegaard Dahlrot, K. de Stricker, Henning B. Boldt, Steinbjørn Hansen, S. Fosmark, Roger Henriksson, Mia D. Sørensen, Bjarne Winther Kristensen

Publikováno v: Dahlrot, R H, Dowsett, J, Fosmark, S, Malmström, A, Henriksson, R, Boldt, H B, de Stricker, K, Sørensen, M D, Poulsen, H S, Lysiak, M, Söderkvist, P, Rosell, J, Hansen, S & Kristensen, B W 2018, ' Prognostic value of O-6-methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis ', Neuropathology and Applied Neurobiology, vol. 44, no. 2, pp. 172-184 . https://doi.org/10.1111/nan.12415

Aims: It is important to predict response to treatment with temozolomide (TMZ) in glioblastoma (GBM) patients. Both MGMT protein expression and MGMT promoter methylation status have been reported to predict the response to TMZ. We investigated the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6187a68dafc11e6d750fb45477c1ff6f
https://doi.org/10.1111/nan.12415